Abbott Laboratories Form 4 insider transactions

Executive Vice President Louis H. Morrone reports the disposition of Abbott Laboratories common shares, including those withheld for tax obligations and shares sold on the market.

Executive Vice President Mary K. Moreland of Abbott Laboratories reports the disposition and acquisition of company stock, including shares sold to cover tax obligations.

John A. McCoy, Jr., Vice President and Controller of Abbott Laboratories, reports the disposition and acquisition of company stock.

Robert B. Ford, Chairman and CEO of Abbott Laboratories, reported the disposal of 31,651 common shares to cover tax obligations.

Lisa D. Earnhardt, EVP and Group President at Abbott Laboratories, reported disposing of 8,322 common shares on February 28, 2025.

Philip P. Boudreau, EVP and CFO of Abbott Laboratories, reports a disposition of 4,908 common shares to cover tax obligations, leaving a direct holding of 56,553 shares and an indirect holding of 360 shares through a Profit Sharing Trust.

Executive Vice President Hubert L. Allen of Abbott Laboratories reports disposing of 8,382 common shares to cover tax obligations.

Executive Vice President Andrea F. Wainer reports acquisition of Abbott Laboratories stock and options under the company's incentive programs.

Daniel Gesua Sive Salvadori, Executive Vice President of Abbott Laboratories, reports acquisition of common shares and stock options.

Louis H. Morrone, Executive Vice President of Abbott Laboratories, reports acquisition of shares and options, including a performance-based restricted stock award and employee stock options.

Mary K. Moreland, Executive Vice President of Abbott Laboratories, reports acquisition of shares and options, including performance-based restricted stock and employee stock options.

John A. McCoy, Jr., Vice President of Abbott Laboratories, reports acquisition of shares and options, including a performance-based restricted stock award, in a recent SEC filing.

Abbott Laboratories CEO Robert B. Ford reports the acquisition of performance-based restricted stock and stock options, along with the disposition of shares held in a family trust.

Executive Vice President Lisa D. Earnhardt acquired shares and options in Abbott Laboratories on February 25, 2025, according to a Form 4 filing.

Executive Vice President Philip P. Boudreau reports acquisition and disposal of Abbott Laboratories shares and stock options.

Executive Vice President Hubert L. Allen reports the acquisition of Abbott Laboratories shares through a performance-based restricted stock award and an employee stock option grant.

Abbott Laboratories CEO Robert Ford exercised stock options and sold a portion of the acquired shares on February 5, 2025.

Executive Vice President of Abbott Laboratories, Hubert L. Allen, exercised stock options and sold shares on January 29th and 30th, 2025.

Daniel Gesua Sive Salvadori, an Executive Vice President at Abbott Laboratories, exercised stock options and sold a portion of the acquired shares on January 30, 2025.

Executive Vice President of Abbott Laboratories, Louis H. Morrone, sold 2,644 common shares on January 28, 2025.

Director John G. Stratton acquired 324 stock equivalent units of Abbott Laboratories on December 31, 2024, through director fees credited to a grantor trust.

Director Michael F. Roman reported the acquisition of 311 stock equivalent units in Abbott Laboratories on December 31, 2024, according to a Form 4 filing.

Director Patricia Paola Gonzalez reports acquisition of 291 stock equivalent units in Abbott Laboratories on December 31, 2024, through director fees credited to a grantor trust.

Director Robert J. Alpern reports acquisition of 69 stock equivalent units in Abbott Laboratories on December 31, 2024, through director fees credited to a grantor trust.

Executive Vice President Hubert L. Allen of Abbott Laboratories reports the exercise of stock options and subsequent sale of shares on October 21, 2024.

Director John G. Stratton reports acquisition of 322 stock equivalent units in Abbott Laboratories through director fees.

Director Michael F. Roman reports acquisition of Abbott Laboratories stock equivalent units through director fees.

Director Patricia Paola Gonzalez reports acquisition of 289 stock equivalent units in Abbott Laboratories through director fees credited to a grantor trust.

Director Robert J. Alpern reports acquisition of 69 stock equivalent units in Abbott Laboratories on September 30, 2024, through director fees credited to a grantor trust.

Abbott Laboratories CEO Robert Ford exercised stock options and sold shares on September 12, 2024, according to a Form 4 filing with the SEC.